Citations (62)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Verena Gotta, Kim Dao, Frédérique Rodieux, Thierry Buclin, Françoise Livio & Marc Pfister. (2017) Guidance to develop individual dose recommendations for patients on chronic hemodialysis. Expert Review of Clinical Pharmacology 10:7, pages 737-752.
Read now
Read now
Ravi Kanth Bhamidipati, Ramesh Mullangi & Nuggehally R. Srinivas. (2017) Interspecies scaling of urinary excretory amounts of nine drugs belonging to different therapeutic areas with diverse chemical structures – accurate prediction of the human urinary excretory amounts . Xenobiotica 47:2, pages 112-118.
Read now
Read now
Articles from other publishers (60)
Behnam Noorani, Rajeev M. Menon, Xin Chen, Kennan C. Marsh, Weize Huang, Shelly Gupta, Edyta Dobkowska, Thomas Marbury & Ahmed Hamed Salem. (2023) Venetoclax pharmacokinetics in participants with end‐stage renal disease undergoing haemodialysis. British Journal of Clinical Pharmacology.
Crossref
Crossref
Hiroyuki Nishiyama, Takamitsu Inoue, Yuichi Koizumi, Yusuke Kobayashi, Hiroshi Kitamura, Kazuhiro Yamamoto, Takashi Takeda, Takehito Yamamoto, Ryohei Yamamoto, Takeshi Matsubara, Junichi Hoshino & Motoko Yanagita. (2023) Chapter 2:indications and dosing of anticancer drug therapy in patients with impaired kidney function, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022. International Journal of Clinical Oncology.
Crossref
Crossref
Fawaz Alasmari, Mohammed S. Alasmari, Hussa Mubarak Muwainea, Hatun A. Alomar, Abdullah F. Alasmari, Sary Alsanea, Aws Alshamsan, Muhammad F. Rasool & Faleh Alqahtani. (2023) Physiologically-based pharmacokinetic modeling for single and multiple dosing regimens of ceftriaxone in healthy and chronic kidney disease populations: a tool for model-informed precision dosing. Frontiers in Pharmacology 14.
Crossref
Crossref
Catharina H. M. Kerskes, Carien J. M. E. van den Eijnde, Albert-Jan L. H. J. Aarnoudse, René J. E. Grouls, Birgit A. L. M. Deiman & Maarten J. Deenen. (2023) The Effect of Genotyping on the Number of Pharmacotherapeutic Gene–Drug Interventions in Chronic Kidney Disease Patients. Pharmacy 11:2, pages 69.
Crossref
Crossref
Kamila Wala-Zielińska, Karolina Świerczyńska-Mróz, Piotr K. Krajewski, Danuta Nowicka-Suszko, Magdalena Krajewska & Jacek C. Szepietowski. (2023) Endogenous Opioid Imbalance as a Potential Factor Involved in the Pathogenesis of Chronic Kidney Disease-Associated Pruritus in Dialysis Patients. Journal of Clinical Medicine 12:7, pages 2474.
Crossref
Crossref
Paul Matte, Kevin Bihan, Corinne Isnard-Bagnis, Noël Zahr, Antoine Thiery-Vuillemin, Paul Gougis & Luca Campedel. (2023) Management of cancer treatments in hemodialysis patients. Bulletin du Cancer.
Crossref
Crossref
Didem Turgut. 2023. Management of Chronic Kidney Disease. Management of Chronic Kidney Disease
429
437
.
Clarisse Roux, Kristelle Verollet, Julien Prouvot, Camelia Prelipcean, Emilie Pambrun & Olivier Moranne. (2022) Choosing the right chronic medication for hemodialysis patients. A short ABC for the dialysis nephrologist. Journal of Nephrology 36:2, pages 521-536.
Crossref
Crossref
Faten Farouk, Ibrahim M Ibrahim, Ehab ElKady, Sherif Mogawer, Shaimaa Elkholy, Ahmed Elmeligui, Reham Abdelghani, Salwa Ibrahim & Dina Wahba. (2022) Assessment of alteration in antiviral plasma concentration across dialysis days: computational and analytical study. Bioanalysis 14:24, pages 1563-1581.
Crossref
Crossref
Hafsa Hafsa, Ammara Zamir, Muhammad Fawad Rasool, Imran Imran, Hamid Saeed, Tanveer Ahmad, Sary Alsanea, Ali A. Alshamrani, Abdullah H. Alruwaili & Faleh Alqahtani. (2022) Development and Evaluation of a Physiologically Based Pharmacokinetic Model of Labetalol in Healthy and Diseased Populations. Pharmaceutics 14:11, pages 2362.
Crossref
Crossref
Susan J. Lewis, Damon Bodenhorn, Eun‐Young Na & Soo Min Jang. (2021) Comparison of antimicrobial dosing recommendations in patients receiving intermittent hemodialysis among drug information resources. Journal of Clinical Pharmacy and Therapeutics 47:5, pages 628-635.
Crossref
Crossref
Elodie MatusikClément BoidinArnaud FriggeriJean-Christophe RichardLaurent BitkerJason A. RobertsSylvain Goutelle. (2022) Therapeutic Drug Monitoring of Antibiotic Drugs in Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis: A Critical Review. Therapeutic Drug Monitoring 44:1, pages 86-102.
Crossref
Crossref
Poh Choo How & Glen Xiong. 2022. Psychonephrology. Psychonephrology
73
89
.
Mara Medeiros & Guido Filler. 2022. Pediatric Nephrology. Pediatric Nephrology
2031
2045
.
Sudhir K Bowry, Fatih Kircelli, Mooppil Nandakumar & Tushar J Vachharajani. (2021) Clinical relevance of abstruse transport phenomena in haemodialysis. Clinical Kidney Journal 14:Supplement_4, pages i85-i97.
Crossref
Crossref
Nanno Schreuder, Iris de Romijn, Pieter L. Jager, Jos G. W. Kosterink & Eugène P. van Puijenbroek. (2021) Safe use of radiopharmaceuticals in patients with chronic kidney disease: a systematic review. EJNMMI Radiopharmacy and Chemistry 6:1.
Crossref
Crossref
Conor Judge, Robert Murphy, Catriona Reddin, Sarah Cormican, Andrew Smyth, Martin O’Halloran & Martin J. O’Donnell. (2021) Trends in Adaptive Design Methods in Dialysis Clinical Trials: A Systematic Review. Kidney Medicine 3:6, pages 925-941.
Crossref
Crossref
Paulien Ravenstijn, Manoranjenni Chetty & Pooja Manchandani. (2021) Design and conduct considerations for studies in patients with impaired renal function. Clinical and Translational Science 14:5, pages 1689-1704.
Crossref
Crossref
Sheila Annie Peters. 2021. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations
417
428
.
Leslie Y. Chiang, Brett Baumann, Kamila Romanowski, Divjot Kumar, Jonathon R. Campbell, Ognjenka Djurdjev, Muhammad Morshed, Inna Sekirov, Victoria J. Cook, Adeera Levin & James C. Johnston. (2021) Latent Tuberculosis Therapy Outcomes in Dialysis Patients: A Retrospective Cohort. American Journal of Kidney Diseases 77:5, pages 696-703.
Crossref
Crossref
Roshan Sutar, Mahendra Kumar Atlani & Pooja Chaudhary. (2021) Antipsychotics and hemodialysis: A systematic review. Asian Journal of Psychiatry 55, pages 102484.
Crossref
Crossref
Paul L. Kimmel, Scott D. Cohen & Daniel Cukor. 2021. Psychosocial Aspects of Chronic Kidney Disease. Psychosocial Aspects of Chronic Kidney Disease
167
181
.
L. Parker Gregg & S. Susan Hedayati. 2021. Psychosocial Aspects of Chronic Kidney Disease. Psychosocial Aspects of Chronic Kidney Disease
91
116
.
Alice Won & Paul L. Kimmel. 2021. Psychosocial Aspects of Chronic Kidney Disease. Psychosocial Aspects of Chronic Kidney Disease
27
48
.
Mara Medeiros & Guido Filler. 2020. Pediatric Nephrology. Pediatric Nephrology
1
15
.
Joseph B. Pryor, Joseph Lockridge & Ali J. Olyaei. 2021. Applied Peritoneal Dialysis. Applied Peritoneal Dialysis
349
374
.
Marios Spanakis, Marianna Roubedaki, Ioannis Tzanakis, Michail Zografakis-Sfakianakis, Evridiki Patelarou & Athina Patelarou. (2020) Impact of Adverse Drug Reactions in Patients with End Stage Renal Disease in Greece. International Journal of Environmental Research and Public Health 17:23, pages 9101.
Crossref
Crossref
So Won Kim, Dong Jin Kim, Dae Young Zang & Dong-Hwan Lee. (2020) Impact of Sampling Period on Population Pharmacokinetic Analysis of Antibiotics: Why do You Take Blood Samples Following the Fourth Dose?. Pharmaceuticals 13:9, pages 249.
Crossref
Crossref
Conor Judge, Robert P Murphy, Sarah Cormican, Andrew Smyth, Martin O'Halloran & Martin O'Donnell. (2020) Adaptive design methods in dialysis clinical trials: a systematic review protocol. BMJ Open 10:8, pages e036755.
Crossref
Crossref
Shuichi Tsuruoka, Takamasa Endo, Mizuna Seo & Naoto Hashimoto. (2020) Pharmacokinetics and Dialyzability of a Single Oral Dose of Amenamevir, an Anti-Herpes Drug, in Hemodialysis Patients. Advances in Therapy 37:7, pages 3234-3245.
Crossref
Crossref
Anne M. Schijvens, Saskia N. de Wildt & Michiel F. Schreuder. (2019) Pharmacokinetics in children with chronic kidney disease. Pediatric Nephrology 35:7, pages 1153-1172.
Crossref
Crossref
Faten Farouk, Dina Wahba, Sherif Mogawer, Shaimaa Elkholy, Ahmed Elmeligui, Reham Abdelghani & Salwa Ibahim. (2019) Development and Validation of a New LC–MS/MS Analytical Method for Direct-Acting Antivirals and Its Application in End-Stage Renal Disease Patients. European Journal of Drug Metabolism and Pharmacokinetics 45:1, pages 89-99.
Crossref
Crossref
L. Parker Gregg & S. Susan Hedayati. 2020. Chronic Renal Disease. Chronic Renal Disease
1123
1140
.
Bradley L. Urquhart & Thomas D. Nolin. 2020. Chronic Renal Disease. Chronic Renal Disease
1035
1051
.
Hongdi Cao. 2020. Chronic Kidney Disease. Chronic Kidney Disease
187
198
.
Salia Farrokh, Abdalla A. Ammar & Kent A. Owusu. 2020. Neurointensive Care Unit. Neurointensive Care Unit
73
85
.
Osama Y. Alshogran. (2019) Warfarin Dosing and Outcomes in Chronic Kidney Disease: A Closer Look at Warfarin Disposition. Current Drug Metabolism 20:8, pages 633-645.
Crossref
Crossref
Yeo Min Yoon, SangMin Kim, Yong-Seok Han, Chul Won Yun, Jun Hee Lee, Hyunjin Noh & Sang Hun Lee. (2019) TUDCA-treated chronic kidney disease-derived hMSCs improve therapeutic efficacy in ischemic disease via PrPC. Redox Biology 22, pages 101144.
Crossref
Crossref
Hadi Molanaei, Abdul Rashid Qureshi, Olof Heimbürger, Bengt Lindholm, Ulf Diczfalusy, Björn Anderstam, Leif Bertilsson & Peter Stenvinkel. (2018) Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients. BMC Pharmacology and Toxicology 19:1.
Crossref
Crossref
Darren M. Roberts, Jacob Sevastos, Jane E. Carland, Sophie L. Stocker & Tom N. Lea-Henry. (2018) Clinical Pharmacokinetics in Kidney Disease. Clinical Journal of the American Society of Nephrology 13:8, pages 1254-1263.
Crossref
Crossref
Alvin Tieu, Thomas J. Velenosi, Andrew S. Kucey, Matthew A. Weir & Bradley L. Urquhart. (2018) β-Blocker Dialyzability in Maintenance Hemodialysis Patients. Clinical Journal of the American Society of Nephrology 13:4, pages 604-611.
Crossref
Crossref
Elisa Borella, Italo Poggesi & Paolo Magni. (2017) Prediction of the Effect of Renal Impairment on the Pharmacokinetics of New Drugs. Clinical Pharmacokinetics 57:4, pages 505-514.
Crossref
Crossref
Emaad Abdel-Kahaar & Oliver Zolk. (2018) Prescribing of anticancer drugs in renal impairment: why can’t we do better?. Naunyn-Schmiedeberg's Archives of Pharmacology 391:2, pages 107-109.
Crossref
Crossref
Eli N. Deal & Jerrica E. Shuster. (2017) Balancing Anticoagulation Decisions in Patients on Dialysis with Atrial Fibrillation. Journal of the American Society of Nephrology 28:7, pages 1957-1959.
Crossref
Crossref
Antoine Thiery-Vuillemin, Emeline Orillard, Guillaume Mouillet, Fabien Calcagno, Nadège Devillard, Stéphane Bouchet & Bernard Royer. (2017) Hemodialysis does not impact axitinib exposure: clinical case of a patient with metastatic renal cell carcinoma. Cancer Chemotherapy and Pharmacology 79:6, pages 1273-1276.
Crossref
Crossref
Tom MunyerRim M. Hadgu & Katie E. Cardone. 2017. PharmacotherapyFirst: A Multimedia Learning Resource. PharmacotherapyFirst: A Multimedia Learning Resource.
M. AL ZA’ABI, A. SHALABY, P. MANOJ & B. H. ALI. (2017) The In Vivo Effects of Adenine-Induced Chronic Kidney Disease on Some Renal and Hepatic Function and CYP450 Metabolizing Enzymes. Physiological Research, pages 263-271.
Crossref
Crossref
Kim Dao, Haithem Chtioui, Yimin Lu, Cody J. Peer, William D. Figg, Menno Pruijm, Thierry Buclin & Sébastien Kissling. (2017) Pharmacokinetics of Pomalidomide in a Patient Receiving Hemodialysis Using a High-Cutoff Filter. American Journal of Kidney Diseases 69:4, pages 553-554.
Crossref
Crossref
T.D. Nolin. 2017. Drug Metabolism in Diseases. Drug Metabolism in Diseases
91
113
.
Scott D. Cohen, Daniel Cukor & Paul L. Kimmel. (2016) Anxiety in Patients Treated with Hemodialysis. Clinical Journal of the American Society of Nephrology 11:12, pages 2250-2255.
Crossref
Crossref
Daniel V. Neves, Vera L. Lanchote, Miguel Moys?s Neto, Jos? A. Cardeal da Costa, Carolina P. Vieira & Eduardo B. Coelho. (2016) Influence of chronic kidney disease and haemodialysis treatment on pharmacokinetics of nebivolol enantiomers. British Journal of Clinical Pharmacology 82:1, pages 83-91.
Crossref
Crossref
Alvin Tieu, Maxwell Leither, Bradley L. Urquhart & Matthew A. Weir. (2016) Clearance of cardiovascular medications during hemodialysis. Current Opinion in Nephrology and Hypertension 25:3, pages 257-267.
Crossref
Crossref
Xiaoli Wang, Giridhar Tirucherai, Thomas C. Marbury, Jessie Wang, Ming Chang, Donglu Zhang, Yan Song, Janice Pursley, Rebecca A. Boyd & Charles Frost. (2016) Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. The Journal of Clinical Pharmacology 56:5, pages 628-636.
Crossref
Crossref
Alvin Tieu, Andrew A. House & Bradley L. Urquhart. (2016) Drug Disposition Issues in CKD: Implications for Drug Discovery and Regulatory Approval. Advances in Chronic Kidney Disease 23:2, pages 63-66.
Crossref
Crossref
Guido Filler, Amrit Kirpalani & Bradley L. Urquhart. 2016. Pediatric Nephrology. Pediatric Nephrology
2267
2293
.
Thomas D. Nolin. (2015) A Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKD. Seminars in Dialysis 28:4, pages 325-329.
Crossref
Crossref
Benjamin K.A. Thomson, Thomas D. Nolin, Thomas J. Velenosi, David A. Feere, Michael J. Knauer, Linda J. Asher, Andrew A. House & Bradley L. Urquhart. (2015) Effect of CKD and Dialysis Modality on Exposure to Drugs Cleared by Nonrenal Mechanisms. American Journal of Kidney Diseases 65:4, pages 574-582.
Crossref
Crossref
D A Feere, T J Velenosi & B L Urquhart. (2015) Effect of erythropoietin on hepatic cytochrome P450 expression and function in an adenine-fed rat model of chronic kidney disease. British Journal of Pharmacology 172:1, pages 201-213.
Crossref
Crossref
Guido Filler, Amrit Kirpalani & Bradley L. Urquhart. 2014. Pediatric Nephrology. Pediatric Nephrology
1
28
.
Thomas J. Velenosi, David A. Feere, Gurjeev Sohi, Daniel B. Hardy & Bradley L. Urquhart. (2014) Decreased nuclear receptor activity and epigenetic modulation associates with down‐regulation of hepatic drug‐metabolizing enzymes in chronic kidney disease. The FASEB Journal 28:12, pages 5388-5397.
Crossref
Crossref